No Data
LAEKNA-B: 2024 ANNUAL REPORT
[Brokerage Focus] FIRST SHANGHAI: Laikang Pharmaceutical (02105) LAE102 is one of the potential heavyweight solutions for reducing lipids and increasing muscle mass.
Jinwu Financial News | FIRST SHANGHAI Research Report indicates that Dr. Lv Xiangyang, the founder of Leka Pharmaceuticals (02105), has over 30 years of research experience in the ActR signaling pathway and was a co-inventor of Novartis's bimagrumab. Among the company's pipeline, LAE102 is currently the most anticipated by the market. LAE102 in combination with semaglutide demonstrated a synergistic effect in reducing fat (40% fat reduction) and protecting muscle in mouse models. From June to December 2024, LAE102 will complete the Phase I single ascending dose (SAD) study in China with five intravenous dosing cohorts and three subcutaneous dosing cohorts targeting obesity indications.
The new generation target for muscle gain and fat loss: Eli Lilly and Co partners with LAEKNA-B (02105), and the USA Phase I clinical trial is about to start.
In April 2025, information from the Global clinical trial registration platform ClinicalTrials indicates that the Hong Kong-listed biotech company Lai Kai Pharmaceutical updated relevant information about its self-developed pipeline LAE102 targeting obesity in a Phase I clinical trial (NCT06908707) in the USA. One notable change is the name of the partner Eli Lilly and Co appearing in the revised clinical protocol.
Hong Kong stocks have fluctuated | The Innovative Drugs Concept has seen significant gains. Institutions state that there is no need to pay tariffs on the licensing fees for Innovative Drugs, and support policies for Innovative Drugs are expected to be gr
The Innovative Drugs Concept has seen significant growth, as of the time of reporting, LAEKNA-B (02105) is up 13.16%, priced at 12.04 Hong Kong dollars; BRII-B (02137) is up 12.35%, priced at 1.82 Hong Kong dollars; CSTONE PHARMA-B (02616) is up 10.88%, priced at 2.65 Hong Kong dollars; BEIGENE (06160) is up 8.27%, priced at 148 Hong Kong dollars; HBM HOLDINGS-B (02142) is up 7.41%, priced at 7.68 Hong Kong dollars.
Hong Kong stock market fluctuation | The Innovative Drugs Concept shows strong performance. Lepu Biotech-B (02157) rises over 18% and LAEKNA-B (02105) rises over 16%.
The Innovative Drugs Concept has shown strong performance. As of the time of writing, Lepu Biopharma-B (02157) is up 18.13%, trading at 4.3 Hong Kong dollars; LAEKNA-B (02105) is up 16.74%, trading at 10.88 Hong Kong dollars; AKESO (09926) is up 11.6%, trading at 82.75 Hong Kong dollars.
Biomedical stocks fell across the board, with VIVA BIOTECH (01873) down 27.54%. The impact of China Securities Co.,Ltd.'s tariff policy on the Industry Chain of pharmaceuticals still has uncertainties.
Jinwu Finance | Biomedical stocks fell across the board, with VIVA BIOTECH (01873) down 27.54%, HBM HOLDINGS-B (02142) down 25.43%, CUTIA-B (02487) down 25.13%, Yiming Angke-B (01541) down 24.73%, CSTONE PHARMA-B (02616) down 24.68%, LAEKNA-B (02105) down 24.38%, WUXI BIO (02269) down 24.02%, JACOBIO-B (01167) down 23.72%, and WUXI XDC (02268) down 23.45%. According to multiple sources.
